Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment-Reference-Cited by-同舟云学术

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment

Published:2021-04-03 Issue:10 Volume:12 Page:1598-1604
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Choi Hayoung¹^ORCID,Lee Jae‐Kyeong²,Oh Hyung‐Joo²^ORCID,Kim Min‐Seok²,Kho Bo Gun²,Park Cheol Kyu²^ORCID,Oh In‐Jae²^ORCID,Kim Young‐Chul²^ORCID

Affiliation:

1. Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine Seoul South Korea

2. Lung and Esophageal Cancer Clinic, Department of Internal Medicine Chonnam National University Medical School, Chonnam National University Hwasun Hospital Hwasun South Korea

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13957

Reference26 articles.

1. Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014

2. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

3. National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology Non‐Small Cell Cancer: NCCN. 2021.https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

4. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

5. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular disease and lung cancer;Frontiers in Oncology;2024-02-12